Literature DB >> 10702546

A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998.

J Andrews1, J Ashby, G Jevons, T Marshall, N Lines, R Wise.   

Abstract

Rates of resistance for two consecutive years for 28 centres (10 Teaching, nine Associate Teaching and nine District General hospitals) in the UK were compared. Combined rates of resistance for each of the hospital types of Staphylococcus aureus to methicillin revealed an increase in the rate of resistance in Teaching hospitals (12.5% year 1, 23.5% year 2), but, for Associate Teaching and District General hospitals rates fell (Associate Teaching 19.1% year 1, 11.9% year 2; District General 16.5% year 1 and 11.3% year 2). Using conventional methodology to determine MICs, no strain was considered to have reduced susceptibility to vancomycin. Among coagulase-negative staphylococci, increased resistance was observed for Staphylococcus epidermidis to rifampicin, for Staphylococcus haemolyticus to clindamycin, for Staphylococcus saprophyticus to penicillin and for Staphylococcus spp. to clindamycin, methicillin and rifampicin. For Streptococcus pneumoniae an upward trend in low-level resistance to penicillin was observed (18 of the 28 centres), however, for high-level resistance the trend was in the opposite direction (only four centres showed an increase). For Enterococcus faecalis there was a trend to a fall in levels of resistance, the only exception being an increase in high-level gentamicin resistance (10.5% year 1, 15.1% year 2, P = 0.0388). For Enterococcus faecium rates of resistance were not significantly different except for increases in resistance to nitrofurantoin and rifampicin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702546     DOI: 10.1093/jac/45.3.285

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Fusidic acid cream for impetigo. Fusidic acid should be used with restraint.

Authors:  Erwin M Brown; Richard Wise
Journal:  BMJ       Date:  2002-06-08

3.  Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health.

Authors: 
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

Review 4.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

5.  R-thanatin inhibits growth and biofilm formation of methicillin-resistant Staphylococcus epidermidis in vivo and in vitro.

Authors:  Zheng Hou; Fei Da; Baohui Liu; Xiaoyan Xue; Xiuli Xu; Ying Zhou; Mingkai Li; Zhi Li; Xue Ma; Jingru Meng; Min Jia; Yukun Wang; Xiaoxing Luo
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

6.  Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004.

Authors:  Edet E Udo; Noura Al-Sweih; Eiman Mokaddas; Molly Johny; Rita Dhar; Huda H Gomaa; Inaam Al-Obaid; Vincent O Rotimi
Journal:  BMC Infect Dis       Date:  2006-11-25       Impact factor: 3.090

7.  Antimicrobial susceptibility, virulence determinants profiles and molecular characteristics of Staphylococcus epidermidis isolates in Wenzhou, eastern China.

Authors:  Yinjuan Guo; Yu Ding; Li Liu; Xiaofei Shen; Zhihao Hao; Jingjing Duan; Ye Jin; Zengqiang Chen; Fangyou Yu
Journal:  BMC Microbiol       Date:  2019-07-09       Impact factor: 3.605

8.  Pandemic flu. Clinical management of patients with an influenza-like illness during an influenza pandemic.

Authors: 
Journal:  J Infect       Date:  2006-12       Impact factor: 6.072

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.